Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 163

1.

A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa.

Lu G, DeGuzman FR, Hollenbach SJ, Karbarz MJ, Abe K, Lee G, Luan P, Hutchaleelaha A, Inagaki M, Conley PB, Phillips DR, Sinha U.

Nat Med. 2013 Apr;19(4):446-51. doi: 10.1038/nm.3102. Epub 2013 Mar 3.

PMID:
23455714
2.

Antidote reverses anticoagulant effects of factor Xa inhibitors in minutes, studies show.

Mayor S.

BMJ. 2015 Nov 12;351:h6086. doi: 10.1136/bmj.h6086. No abstract available.

PMID:
26567177
3.

A rapid pro-hemostatic approach to overcome direct oral anticoagulants.

Thalji NK, Ivanciu L, Davidson R, Gimotty PA, Krishnaswamy S, Camire RM.

Nat Med. 2016 Aug;22(8):924-32. doi: 10.1038/nm.4149. Epub 2016 Jul 25.

PMID:
27455511
4.

Clinical implications of reversal agents for direct oral anticoagulants.

Monagle S, Eikelboom JW, Ng KH, Bhagirath VC.

Future Cardiol. 2017 Mar;13(2):153-159. doi: 10.2217/fca-2016-0070. Epub 2017 Feb 13. Review.

PMID:
28198201
5.

Reversal of anticoagulants: an overview of current developments.

Greinacher A, Thiele T, Selleng K.

Thromb Haemost. 2015 May;113(5):931-42. doi: 10.1160/TH14-11-0982. Epub 2015 Apr 2. Review.

PMID:
25832311
6.

Andexanet: Effectively Reversing Anticoagulation.

Lippi G, Sanchis-Gomar F, Favaloro EJ.

Trends Pharmacol Sci. 2016 Jun;37(6):413-414. doi: 10.1016/j.tips.2016.03.002. Epub 2016 Apr 2.

PMID:
27048885
8.

Andexanet alfa for the reversal of Factor Xa inhibitor related anticoagulation.

Ghadimi K, Dombrowski KE, Levy JH, Welsby IJ.

Expert Rev Hematol. 2016;9(2):115-22. doi: 10.1586/17474086.2016.1135046. Review.

PMID:
26686866
9.

Preclinical and Clinical Data for Factor Xa and "Universal" Reversal Agents.

Milling TJ Jr, Kaatz S.

Am J Med. 2016 Nov;129(11S):S80-S88. doi: 10.1016/j.amjmed.2016.06.009. Epub 2016 Aug 27. Review.

10.

Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity.

Siegal DM, Curnutte JT, Connolly SJ, Lu G, Conley PB, Wiens BL, Mathur VS, Castillo J, Bronson MD, Leeds JM, Mar FA, Gold A, Crowther MA.

N Engl J Med. 2015 Dec 17;373(25):2413-24. doi: 10.1056/NEJMoa1510991. Epub 2015 Nov 11.

11.

Discontinuation and Management of Direct-Acting Anticoagulants for Emergency Procedures.

Levy JH.

Am J Med. 2016 Nov;129(11S):S47-S53. doi: 10.1016/j.amjmed.2016.06.005. Epub 2016 Aug 26. Review.

12.

Impact of antithrombin deficiency on efficacy of edoxaban and antithrombin-dependent anticoagulants, fondaparinux, enoxaparin, and heparin.

Fukuda T, Kamisato C, Honda Y, Matsushita T, Kojima T, Furugohri T, Morishima Y, Shibano T.

Thromb Res. 2013 Jun;131(6):540-6. doi: 10.1016/j.thromres.2013.04.016. Epub 2013 May 11.

PMID:
23673387
13.

Andexanet alfa: a recombinant mimetic of human factor Xa for the reversal of anticoagulant therapies.

Escolar G, Diaz-Ricart M, Arellano-Rodrigo E.

Drugs Today (Barc). 2017 May;53(5):271-282. doi: 10.1358/dot.2017.53.5.2630780. Review.

PMID:
28650000
14.

Development of a recombinant antithrombin variant as a potent antidote to fondaparinux and other heparin derivatives.

Bianchini EP, Fazavana J, Picard V, Borgel D.

Blood. 2011 Feb 10;117(6):2054-60. doi: 10.1182/blood-2010-06-288522. Epub 2010 Nov 3.

15.

Inactivated antithrombins as fondaparinux antidotes: a promising alternative to haemostatic agents as assessed in vitro in a thrombin-generation assay.

Bourti Y, Fazavana J, Armand M, Saller F, Lasne D, Borgel D, Bianchini EP.

Thromb Haemost. 2016 Aug 30;116(3):452-60. doi: 10.1160/TH15-12-0927. Epub 2016 Jul 14.

PMID:
27412396
16.

Cardiology Patient Pages: Antidotes for Bleeding Caused by Novel Oral Anticoagulants.

Pollack CV Jr.

Circulation. 2016 Jan 12;133(2):e18-9. doi: 10.1161/CIRCULATIONAHA.115.018355. No abstract available.

17.

Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects.

Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M.

Circulation. 2011 Oct 4;124(14):1573-9. doi: 10.1161/CIRCULATIONAHA.111.029017. Epub 2011 Sep 6.

18.
19.

Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor dabigatran in rabbits.

Wong PC, Crain EJ, Watson CA, Xin B.

J Thromb Haemost. 2009 Aug;7(8):1313-20. doi: 10.1111/j.1538-7836.2009.03503.x. Epub 2009 Jun 3.

20.

Antithrombotic and anticoagulant profiles of TAK-442, a novel factor Xa inhibitor, in a rabbit model of venous thrombosis.

Kawamura M, Konishi N, Hiroe K, Shofuda K, Imaeda Y, Fujimoto T, Kubo K.

J Cardiovasc Pharmacol. 2010 Aug;56(2):156-61. doi: 10.1097/FJC.0b013e3181e2bfcf. Erratum in: J Cardiovasc Pharmacol. 2010 Oct;56(4):439.

PMID:
20410831

Supplemental Content

Support Center